New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency

Botulinum neurotoxins (BoNTs) are notorious toxins and powerful agents and can be lethal, causing botulism, but they are also widely used as therapeutics, particularly to treat neuromuscular disorders. As of today, the commercial BoNT treatments available are from native A or B serotypes. Serotype F has shown efficacy in a clinical trial but has scarcely been used, most likely due to its medium duration of effect. Previously, the uniqueness of the light chain of the F7 subtype was identified and reported, showing an extended interaction with its substrates, VAMPs 1, 2 and 3, and a superior catalytic activity compared to other BoNT/F subtypes. In order to more extensively study the properties of this neurotoxin, we engineered a modified F7 chimera, mrBoNT/F7-1, in which all the regions of the neurotoxin were identical to BoNT/F7 except the activation loop, which was the activation loop from BoNT/F1. Use of the activation loop from BoNT/F1 allowed easier post-translational proteolytic activation of the recombinant protein without otherwise affecting its properties. mrBoNT/F7-1 was expressed, purified and then tested in a suite of in vitro and in vivo assays. mrBoNT/F7-1 was active and showed enhanced potency in comparison to both native and recombinant BoNT/F1. Additionally, the safety profile remained comparable to BoNT/F1 despite the increased potency. This new modified recombinant toxin F7 could be further exploited to develop unique therapeutics to address unmet medical needs. View Full-Text

Keywords: botulinum neurotoxin; recombinant protein; potency; safety profile; in vivo

▼ Show Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Supplementary Material

Supplementary File 1:
ZIP-Document (ZIP, 478 KiB)

Share and Cite

MDPI and ACS Style

Burgin, D.; Périer, C.; Hackett, G.; Elliott, M.; Kwan, D.; Hornby, F.; Mir, I.; Maignel, J.; Liu, S.M.; Beard, M. New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency. Toxins 2021, 13, 834. https://doi.org/10.3390/toxins13120834

AMA Style

Burgin D, Périer C, Hackett G, Elliott M, Kwan D, Hornby F, Mir I, Maignel J, Liu SM, Beard M. New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency. Toxins. 2021; 13(12):834. https://doi.org/10.3390/toxins13120834

Chicago/Turabian Style

Burgin, David, Cindy Périer, Gavin Hackett, Mark Elliott, Daniel Kwan, Fraser Hornby, Imran Mir, Jacquie Maignel, Sai M. Liu, and Matthew Beard. 2021. "New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency" Toxins 13, no. 12: 834. https://doi.org/10.3390/toxins13120834

Find Other Styles

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Abstract views Pdf views Html views

Article Menu

New Modified Recombinant Botulinum Neurotoxin Type F with Enhanced Potency

Abstract

Supplementary Material

Share and Cite

Article Metrics

Article Access Statistics

Article Access Map by Country/Region

Further Information

Guidelines

MDPI Initiatives

Follow MDPI